Particle potency estimates | Particles | Ranking in vitro | Ranking in vivo | Rank-order correl. (All PM)a | Rank-order correl. (no CRI)b | ||||
---|---|---|---|---|---|---|---|---|---|
R | p (1-tailed) | R | p (1-tailed) | ||||||
Toxicity  βR CELLS vs. βT BALB/c | CRI | 5 | - | 3 | - |  |  |  |  |
DWR1 | 4 | (4) | 5 | (4) | Â | Â | Â | Â | |
EHC-2000 | 2 | (2) | 2 | (2) | 0.667 | 0.109 | 1.000 | <0.001 | |
SRM-1649 | 1 | (1) | 1 | (1) | Â | Â | Â | Â | |
TiO2 | 3 | (3) | 4 | (3) | Â | Â | Â | Â | |
Inflammation  βI-V CELLS vs. βI BALB/c | CRI | 4 | - | 3 | - |  |  |  |  |
DWR1 | 5 | (4) | 5 | (4) | Â | Â | Â | Â | |
EHC-2000 | 1 | (1) | 2 | (2) | 0.800 | 0.052 | 0.800 | 0.100 | |
SRM-1649 | 2 | (2) | 1 | (1) | Â | Â | Â | Â | |
TiO2 | 3 | (3) | 4 | (3) | Â | Â | Â | Â | |
Integrated Potency  Iβ CELLS vs. Iβ BALB/c | CRI | 4 | - | 3 | - |  |  |  |  |
DWR1 | 5 | (4) | 5 | (4) | Â | Â | Â | Â | |
EHC-2000 | 1 | (1) | 2 | (2) | 0.800 | 0.052 | 0.800 | 0.100 | |
SRM-1649 | 2 | (2) | 1 | (1) | Â | Â | Â | Â | |
TiO2 | 3 | (3) | 4 | (3) | Â | Â | Â | Â |